Swiss National Bank Has $2.69 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Swiss National Bank grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 28.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,200 shares of the company's stock after acquiring an additional 17,200 shares during the quarter. Swiss National Bank owned 0.14% of Harmony Biosciences worth $2,691,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of HRMY. Ruffer LLP acquired a new position in Harmony Biosciences during the fourth quarter worth $2,598,000. Amundi lifted its position in Harmony Biosciences by 243.3% during the 4th quarter. Amundi now owns 18,402 shares of the company's stock worth $635,000 after buying an additional 13,041 shares in the last quarter. Capital Management Corp VA boosted its stake in shares of Harmony Biosciences by 43.5% during the 4th quarter. Capital Management Corp VA now owns 340,960 shares of the company's stock worth $11,732,000 after buying an additional 103,308 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after acquiring an additional 519 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Harmony Biosciences in the fourth quarter valued at about $1,304,000. Institutional investors and hedge funds own 86.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Mizuho increased their price target on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. HC Wainwright lowered their target price on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, February 25th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $53.33.

Remove Ads

Insider Buying and Selling

In related news, CFO Sandip Kapadia sold 25,000 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jeffrey M. Dayno sold 19,293 shares of the business's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,452 shares of company stock valued at $2,831,679. Insiders own 30.80% of the company's stock.

Harmony Biosciences Stock Performance

Shares of NASDAQ:HRMY remained flat at $33.19 on Monday. 535,977 shares of the company's stock traded hands, compared to its average volume of 552,986. The stock's fifty day moving average is $35.90 and its 200 day moving average is $35.44. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The company has a market cap of $1.90 billion, a PE ratio of 15.73, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 12-month low of $28.14 and a 12-month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the prior year, the business earned $0.45 EPS. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. Sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.